Policy implications of rationalization of statin use in Lithuania

Edmundas Kadusevicius, Danguole Jankauskiene, Inga Paulauskaite, Rimvydas Slapikas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The aim of this study was to assess the trends and costs of statin use in Lithuania over a 3-year period and perform a cost-minimization and reference price analysis to rationalize the use of financial resources of the National Health Care System. Methods: The defined daily dose (DDD) methodology was applied for assessment of statin use, which was expressed in DDD/1,000 inhabitants/day. Cost minimization and reference price calculations were used in the economic analysis. Results: Over the 3-year period (2005-2007), the consumption and expenditures of statins in Lithuania doubled. The consumption went up from 3.87 DDD/1,000 inhabitants/day (in 2005) to 8.35 DDD/1,000 inhabitants/day (in 2007). Total expenses of statins increased during the same period from LTL6.186 million in 2005 to LTL12.418 million in 2007. Approximately 68 percent of the estimated costs for statins in 2007 were for atorvastatin. Provided that the calculated reference prices were fixed, the estimated savings would amount to a minimum of LTL1.371 million per year and could reach yearly savings in the order of LTL3.163 million. The total expenses would drop by at least 11 percent, and the decrease in costs could be as high as 25 percent (€1 = LTL3.4528). Conclusions: Statins consumption is still very low in Lithuania in comparison with other European Union countries. Implementation of cholesterol education programs and changing reimbursement profile for statins therapy will increase consumption and expenditures. The introduction of reference-based pricing as an indirect cost control policy would help rationalizing the use of statins and their expenditures.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalInternational Journal of Technology Assessment in Health Care
Volume25
Issue number3
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Lithuania
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Costs and Cost Analysis
Health Expenditures
Cost Control
European Union
Cholesterol
Economics
Delivery of Health Care
Education

Keywords

  • Cost minimization
  • Economics
  • Epidemiology
  • Reference price
  • Statins

ASJC Scopus subject areas

  • Health Policy

Cite this

Policy implications of rationalization of statin use in Lithuania. / Kadusevicius, Edmundas; Jankauskiene, Danguole; Paulauskaite, Inga; Slapikas, Rimvydas.

In: International Journal of Technology Assessment in Health Care, Vol. 25, No. 3, 07.2009, p. 419-424.

Research output: Contribution to journalArticle

Kadusevicius, Edmundas ; Jankauskiene, Danguole ; Paulauskaite, Inga ; Slapikas, Rimvydas. / Policy implications of rationalization of statin use in Lithuania. In: International Journal of Technology Assessment in Health Care. 2009 ; Vol. 25, No. 3. pp. 419-424.
@article{82a3456da6e747d0be220771af48aa9d,
title = "Policy implications of rationalization of statin use in Lithuania",
abstract = "Objectives: The aim of this study was to assess the trends and costs of statin use in Lithuania over a 3-year period and perform a cost-minimization and reference price analysis to rationalize the use of financial resources of the National Health Care System. Methods: The defined daily dose (DDD) methodology was applied for assessment of statin use, which was expressed in DDD/1,000 inhabitants/day. Cost minimization and reference price calculations were used in the economic analysis. Results: Over the 3-year period (2005-2007), the consumption and expenditures of statins in Lithuania doubled. The consumption went up from 3.87 DDD/1,000 inhabitants/day (in 2005) to 8.35 DDD/1,000 inhabitants/day (in 2007). Total expenses of statins increased during the same period from LTL6.186 million in 2005 to LTL12.418 million in 2007. Approximately 68 percent of the estimated costs for statins in 2007 were for atorvastatin. Provided that the calculated reference prices were fixed, the estimated savings would amount to a minimum of LTL1.371 million per year and could reach yearly savings in the order of LTL3.163 million. The total expenses would drop by at least 11 percent, and the decrease in costs could be as high as 25 percent (€1 = LTL3.4528). Conclusions: Statins consumption is still very low in Lithuania in comparison with other European Union countries. Implementation of cholesterol education programs and changing reimbursement profile for statins therapy will increase consumption and expenditures. The introduction of reference-based pricing as an indirect cost control policy would help rationalizing the use of statins and their expenditures.",
keywords = "Cost minimization, Economics, Epidemiology, Reference price, Statins",
author = "Edmundas Kadusevicius and Danguole Jankauskiene and Inga Paulauskaite and Rimvydas Slapikas",
year = "2009",
month = "7",
doi = "10.1017/S0266462309990158",
language = "English",
volume = "25",
pages = "419--424",
journal = "International Journal of Technology Assessment in Health Care",
issn = "0266-4623",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Policy implications of rationalization of statin use in Lithuania

AU - Kadusevicius, Edmundas

AU - Jankauskiene, Danguole

AU - Paulauskaite, Inga

AU - Slapikas, Rimvydas

PY - 2009/7

Y1 - 2009/7

N2 - Objectives: The aim of this study was to assess the trends and costs of statin use in Lithuania over a 3-year period and perform a cost-minimization and reference price analysis to rationalize the use of financial resources of the National Health Care System. Methods: The defined daily dose (DDD) methodology was applied for assessment of statin use, which was expressed in DDD/1,000 inhabitants/day. Cost minimization and reference price calculations were used in the economic analysis. Results: Over the 3-year period (2005-2007), the consumption and expenditures of statins in Lithuania doubled. The consumption went up from 3.87 DDD/1,000 inhabitants/day (in 2005) to 8.35 DDD/1,000 inhabitants/day (in 2007). Total expenses of statins increased during the same period from LTL6.186 million in 2005 to LTL12.418 million in 2007. Approximately 68 percent of the estimated costs for statins in 2007 were for atorvastatin. Provided that the calculated reference prices were fixed, the estimated savings would amount to a minimum of LTL1.371 million per year and could reach yearly savings in the order of LTL3.163 million. The total expenses would drop by at least 11 percent, and the decrease in costs could be as high as 25 percent (€1 = LTL3.4528). Conclusions: Statins consumption is still very low in Lithuania in comparison with other European Union countries. Implementation of cholesterol education programs and changing reimbursement profile for statins therapy will increase consumption and expenditures. The introduction of reference-based pricing as an indirect cost control policy would help rationalizing the use of statins and their expenditures.

AB - Objectives: The aim of this study was to assess the trends and costs of statin use in Lithuania over a 3-year period and perform a cost-minimization and reference price analysis to rationalize the use of financial resources of the National Health Care System. Methods: The defined daily dose (DDD) methodology was applied for assessment of statin use, which was expressed in DDD/1,000 inhabitants/day. Cost minimization and reference price calculations were used in the economic analysis. Results: Over the 3-year period (2005-2007), the consumption and expenditures of statins in Lithuania doubled. The consumption went up from 3.87 DDD/1,000 inhabitants/day (in 2005) to 8.35 DDD/1,000 inhabitants/day (in 2007). Total expenses of statins increased during the same period from LTL6.186 million in 2005 to LTL12.418 million in 2007. Approximately 68 percent of the estimated costs for statins in 2007 were for atorvastatin. Provided that the calculated reference prices were fixed, the estimated savings would amount to a minimum of LTL1.371 million per year and could reach yearly savings in the order of LTL3.163 million. The total expenses would drop by at least 11 percent, and the decrease in costs could be as high as 25 percent (€1 = LTL3.4528). Conclusions: Statins consumption is still very low in Lithuania in comparison with other European Union countries. Implementation of cholesterol education programs and changing reimbursement profile for statins therapy will increase consumption and expenditures. The introduction of reference-based pricing as an indirect cost control policy would help rationalizing the use of statins and their expenditures.

KW - Cost minimization

KW - Economics

KW - Epidemiology

KW - Reference price

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=70350464610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350464610&partnerID=8YFLogxK

U2 - 10.1017/S0266462309990158

DO - 10.1017/S0266462309990158

M3 - Article

C2 - 19619363

AN - SCOPUS:70350464610

VL - 25

SP - 419

EP - 424

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

SN - 0266-4623

IS - 3

ER -